Inventiva signs over China NASH rights to Sino Biopharm in possible $300M+ deal
More than two years after claiming a Phase II win in one of the most challenging diseases faced in biotech, Inventiva is handing over rights in several Asian markets to a more on-site company.
Inventiva and Sino Biopharm jointly announced the deal Wednesday after market close, where Inventiva will hand over development and commercialization rights for NASH candidate lanifibranor to Sino Biopharm subsidiary Chia Tai-Tianqing Pharmaceutical Group (CTTQ). Rights include those in China, Hong Kong, Macau and Taiwan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.